Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
One of the benefits to raking in $6.7 billion in free cash flow is that you can splurge a little if you don't feel like developing something in-house.
Such is the case with Merck (NYSE: MRK ) getting into the follow-on biologics industry -- making copycat versions of biologic drugs -- which the company announced back in December. But bioreactors take time to build, and developing manufacturing processes for producing protein-based biologics isn't as simple as for small molecule drugs. So Merck has decided to go the easy route, and buy something that's already established.
The drugmaker is paying $130 million for Insmed's (Nasdaq: INSM ) manufacturing facility and its follow-on biologics pipeline, including copycats of Amgen's (Nasdaq: AMGN ) Neupogen and Neulasta. The drugs, which boost white blood cells in cancer patients, combined to bring in more than $4.6 billion in worldwide sales last year. That's no small potatoes, even if Merck will have to offer them at a discount.
Merck and Eli Lilly (NYSE: LLY ) , which has also said it's interested in jumping into follow-on biologics, are behind other drugmakers like Teva Pharmaceutical (Nasdaq: TEVA ) , Novartis (NYSE: NVS ) , and Hospira (NYSE: HSP ) that already have approvals in the European Union. The U.S. market is presumably larger, but Congress hasn't set up a system for the Food and Drug Administration to approve the follow-on biologics.
The purchase by Merck helps it catch up a little, and it should put the company in a good position to be able to submit a marketing application in the U.S., once the FDA starts accepting them. When it comes to revenue growth, Merck can certainly use all the help it can get.